previously

CORRECTING and REPLACING Hartford Bakery, Inc. Issues Allergy Alert on Undeclared Hazelnuts in Lewis Bake Shop Artisan Style 1/2 Loaf

EVANSVILLE, Ind.--(BUSINESS WIRE)--This updated release corrects the previously reported lot codes included in the press release dated July 10, 2025.…

2 weeks ago

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

June 20, 2025 17:00 ET  | Source: Inozyme Pharma Inc. BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc.…

1 month ago

Hexagon launches AEON, a humanoid built for industry

Hexagon leverages industry-leading expertise in measurement technologies, AI and autonomous systems to introduce an advanced humanoid robot to accelerate next-generation…

1 month ago

Draganfly Announces Additional Exercise Of Over-Allotment Option

Saskatoon, SK., June 06, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”),…

2 months ago

CITGO Sale Hearing Date Rescheduled to August 18, 2025

PEMBROKE, Bermuda--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces that today the U.S. District…

2 months ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 05, 2025 16:58 ET  | Source: Boundless Bio, Inc. SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio…

2 months ago

ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)

June 05, 2025 16:31 ET  | Source: ImPact Biotech –  Previously inoperable patient converted to eligible for resection, underwent pancreaticoduodenectomy,…

2 months ago

HOTEL101 PROGRESSES TOWARDS NASDAQ LISTING

U.S. SEC DECLARES FORM F-4 SEC REGISTRATION EFFECTIVE SINGAPORE, June 2, 2025 /PRNewswire/ -- Hotel101 Global Holdings Corp. ("Hotel101" or…

2 months ago

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer

Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1…

2 months ago